Medical Information
United States

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Información selecta para pacientes y cuidadores que se encuentra disponible en Español.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

NEURONTIN®Highlights (gabapentin)


These highlights do not include all the information needed to use NEURONTIN safely and effectively. See full prescribing information for NEURONTIN.

NEURONTIN® (gabapentin) capsules, for oral use
NEURONTIN® (gabapentin) tablets, for oral use
NEURONTIN® (gabapentin) oral solution
Initial U.S. Approval: 1993


Warnings and Precautions, Respiratory Depression (5.7)4/2020


NEURONTIN is indicated for:

  • Postherpetic neuralgia in adults (1)
  • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy (1)


  • Postherpetic Neuralgia (2.1)
    • Dose can be titrated up as needed to a dose of 1800 mg/day
    • Day 1: Single 300 mg dose
    • Day 2: 600 mg/day (i.e., 300 mg two times a day)
    • Day 3: 900 mg/day (i.e., 300 mg three times a day)
  • Epilepsy with Partial Onset Seizures (2.2)
    • Patients 12 years of age and older: starting dose is 300 mg three times daily; may be titrated up to 600 mg three times daily
    • Patients 3 to 11 years of age: starting dose range is 10 to 15 mg/kg/day, given in three divided doses; recommended dose in patients 3 to 4 years of age is 40 mg/kg/day, given in three divided doses; the recommended dose in patients 5 to 11 years of age is 25 to 35 mg/kg/day, given in three divided doses. The recommended dose is reached by upward titration over a period of approximately 3 days
  • Dose should be adjusted in patients with reduced renal function (2.3, 2.4)


  • Capsules: 100 mg, 300 mg, and 400 mg (3)
  • Tablets: 600 mg, and 800 mg (3)
  • Oral Solution: 250 mg/5mL (3)


Known hypersensitivity to gabapentin or its ingredients (4)


  • Drug Reaction with Eosinophilia and Systemic Symptoms (Multiorgan hypersensitivity): Discontinue if alternative etiology is not established (5.1)
  • Anaphylaxis and Angioedema: Discontinue and evaluate patient immediately (5.2)
  • Driving Impairment; Somnolence/Sedation and Dizziness: Warn patients not to drive until they have gained sufficient experience to assess whether their ability to drive or operate heavy machinery will be impaired (5.3, 5.4)
  • Increased seizure frequency may occur in patients with seizure disorders if NEURONTIN is abruptly discontinued (5.5)
  • Suicidal Behavior and Ideation: Monitor for suicidal thoughts/behavior (5.6)
  • Respiratory Depression: May occur with NEURONTIN when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment. Monitor patients and adjust dosage as appropriate (5.7)
  • Neuropsychiatric Adverse Reactions in Children 3 to 12 Years of Age: Monitor for such events (5.8)


Most common adverse reactions (incidence ≥8% and at least twice that for placebo) were:

  • Postherpetic neuralgia: Dizziness, somnolence, and peripheral edema (6.1)
  • Epilepsy in patients >12 years of age: Somnolence, dizziness, ataxia, fatigue, and nystagmus (6.1)
  • Epilepsy in patients 3 to 12 years of age: Viral infection, fever, nausea and/or vomiting, somnolence, and hostility (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or


Concentrations increased by morphine; may need dose adjustment (5.4, 7.1)


Pregnancy: Based on animal data, may cause fetal harm (8.1)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 12/2020

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event